JP2013535965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535965A5 JP2013535965A5 JP2013521194A JP2013521194A JP2013535965A5 JP 2013535965 A5 JP2013535965 A5 JP 2013535965A5 JP 2013521194 A JP2013521194 A JP 2013521194A JP 2013521194 A JP2013521194 A JP 2013521194A JP 2013535965 A5 JP2013535965 A5 JP 2013535965A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- sequence
- polynucleotide
- channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 230000000202 analgesic effect Effects 0.000 claims description 10
- 108091006146 Channels Proteins 0.000 claims description 8
- 108010068806 Acid Sensing Ion Channels Proteins 0.000 claims description 5
- 102000001671 Acid Sensing Ion Channels Human genes 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 101000901079 Homo sapiens Acid-sensing ion channel 2 Proteins 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 101000822793 Ophiophagus hannah Alpha-elapitoxin-Oh2b Proteins 0.000 description 1
- 101000822779 Ophiophagus hannah Long neurotoxin 4 Proteins 0.000 description 1
- 101000822798 Ophiophagus hannah Long neurotoxin OH-5 Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1003136A FR2963010B1 (fr) | 2010-07-26 | 2010-07-26 | Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic |
| FR1003136 | 2010-07-26 | ||
| PCT/FR2011/051800 WO2012022894A1 (fr) | 2010-07-26 | 2011-07-26 | Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535965A JP2013535965A (ja) | 2013-09-19 |
| JP2013535965A5 true JP2013535965A5 (enExample) | 2015-09-17 |
| JP6000245B2 JP6000245B2 (ja) | 2016-09-28 |
Family
ID=43589927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013521194A Active JP6000245B2 (ja) | 2010-07-26 | 2011-07-26 | 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8987207B2 (enExample) |
| EP (1) | EP2598523B1 (enExample) |
| JP (1) | JP6000245B2 (enExample) |
| CN (1) | CN103097404B (enExample) |
| AU (1) | AU2011290589A1 (enExample) |
| BR (1) | BR112013001863A2 (enExample) |
| CA (1) | CA2806471C (enExample) |
| FR (1) | FR2963010B1 (enExample) |
| MX (1) | MX336586B (enExample) |
| RU (1) | RU2583299C2 (enExample) |
| SG (1) | SG187877A1 (enExample) |
| WO (1) | WO2012022894A1 (enExample) |
| ZA (1) | ZA201300662B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105233286B (zh) * | 2015-09-10 | 2018-10-30 | 上海交通大学医学院 | 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途 |
| CN105412932B (zh) * | 2015-10-26 | 2019-08-16 | 上海交通大学医学院 | 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途 |
| CN112717135A (zh) * | 2016-11-22 | 2021-04-30 | 上海交通大学医学院 | 酸敏感离子通道调控剂的用途 |
| CN107384952A (zh) * | 2017-08-23 | 2017-11-24 | 湖南甲骨文生物医药有限公司 | 用于筛选ASICs作用蛋白的酵母双杂交诱饵载体的构建方法 |
| KR20220016891A (ko) * | 2019-06-04 | 2022-02-10 | 상하이테크 유니버시티 | 친화성-성숙된 항-ASIC1a 항체 |
| RU2768484C1 (ru) * | 2021-05-24 | 2022-03-24 | Закрытое акционерное общество "СКАЙ ЛТД" | Фармацевтическая композиция иммуностимулирующих веществ мурамилпептидной природы |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776896A (en) | 1996-01-03 | 1998-07-07 | Zeneca Limited | Analgesic peptides from venom of grammostola spatulata and use thereof |
| JP4959226B2 (ja) * | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| JP2008193923A (ja) * | 2007-02-09 | 2008-08-28 | Janusys Kk | 蛋白質ライブラリ |
-
2010
- 2010-07-26 FR FR1003136A patent/FR2963010B1/fr not_active Expired - Fee Related
-
2011
- 2011-07-26 JP JP2013521194A patent/JP6000245B2/ja active Active
- 2011-07-26 CN CN201180043328.6A patent/CN103097404B/zh active Active
- 2011-07-26 WO PCT/FR2011/051800 patent/WO2012022894A1/fr not_active Ceased
- 2011-07-26 US US13/812,457 patent/US8987207B2/en active Active
- 2011-07-26 CA CA2806471A patent/CA2806471C/fr active Active
- 2011-07-26 MX MX2013001020A patent/MX336586B/es unknown
- 2011-07-26 EP EP11752299.5A patent/EP2598523B1/fr active Active
- 2011-07-26 BR BR112013001863A patent/BR112013001863A2/pt not_active Application Discontinuation
- 2011-07-26 AU AU2011290589A patent/AU2011290589A1/en not_active Abandoned
- 2011-07-26 SG SG2013011705A patent/SG187877A1/en unknown
- 2011-07-26 RU RU2013108262/10A patent/RU2583299C2/ru active
-
2013
- 2013-01-24 ZA ZA2013/00662A patent/ZA201300662B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9359405B2 (en) | Antagonists of the interleukin-1 receptor | |
| JP2013535965A5 (enExample) | ||
| EA039105B1 (ru) | Катионные нейротоксины | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| CN104271147A (zh) | 细胞穿膜肽 | |
| JP2014508510A5 (enExample) | ||
| JP2011528332A (ja) | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 | |
| KR20220062668A (ko) | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 | |
| TW201138810A (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
| WO2012127475A1 (en) | Neuroprotective peptides | |
| JP7428404B2 (ja) | Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置 | |
| AU2016277449A1 (en) | Protease-resistant lipidated GLP-1 analogs | |
| JP6953579B2 (ja) | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 | |
| US10881712B2 (en) | Neuroprotective agents derived from spider venom peptides | |
| JP2017524727A5 (enExample) | ||
| CN114751962B (zh) | 订书肽、其制备方法及其制药用途 | |
| EP3116538A1 (en) | Respiratory syncytial virus (rsv) replication inhibitors | |
| CN113474013A (zh) | 肌肉生长抑制素剪接变体衍生蛋白对肌肉生长抑制素信号的抑制及其利用 | |
| JP2016519110A5 (enExample) | ||
| KR20240095008A (ko) | 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도 | |
| CN115974973A (zh) | 一种抑制trpm8的多肽及其用途 | |
| JP2018507854A5 (enExample) | ||
| Class et al. | Patent application title: Antagonists of the Interleukin-1 Receptor Inventors: Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK) Assignees: SERODUS ASA | |
| EP3144007A1 (en) | Peptide for use in the treatment of disease caused by clostridium neurotoxins | |
| EA046580B1 (ru) | Катионные нейротоксины |